[{"id":"37494a36-42c2-4252-ba85-b6ab705daf26","acronym":"","url":"https://clinicaltrials.gov/study/NCT01188499","created_at":"2021-01-18T04:45:11.810Z","updated_at":"2024-07-02T16:37:31.639Z","phase":"Phase 1b/2a","brief_title":"Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT01188499","lead_sponsor":"TetraLogic Pharmaceuticals","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • irinotecan • birinapant (IGM-9427)"],"overall_status":"Completed","enrollment":" Enrollment 176","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 10/01/2013","primary_completion_date":" 10/01/2013","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2016-05-30"}]